Pharmaceuticals Market Research Reports & Industry Analysis
Pharmaceuticals Industry Research & Market Reports
-
Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Pipeline Review, H2 2018
... D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Alpha-galactosidase is a glycoside hydrolase enzyme encoded by the GLA gene. This enzyme is a homodimeric glycoprotein that hydrolyses the terminal alpha-galactosyl ... Read More
-
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2018
... protein encoded by the CCR4 gene. CCR4 is expressed on Th2 T lymphocytes and is up-regulated by T cell receptor activation. This receptor also plays an important role in trafficking of dendritic cells. The CC ... Read More
-
Sub-Saharan Africa Pharmaceuticals & Healthcare Q4 2018
... within the generic medicines sector, while the larger, moredeveloped markets present viable opportunities for patented medicine sales in urban regions. Cooperative agreements withinternational firms will provide opportunities for domestic firms to expand their manufacturing capacities. Read More
-
Middle East And North Africa Pharmaceuticals & Healthcare Q4 2018
... opportunities for multinational drugmakers looking to expand to emergingmarkets. Heightened industry and country risk dissuade company interest and the larger markets dominate multinational activityfor patented medicine sales. Ample opportunities exist in the generics market segment. Read More
-
Europe Pharmaceuticals & Healthcare Q4 2018
... to region-specific trends. Themore developed Western markets will continue to be favoured by innovative drugmakers due to stronger regulatory oversight andgreater purchasing power, although growth in these markets will be suppressed by aggressive cost-containment. Revenue ... Read More
-
Ghana Pharmaceuticals & Healthcare Q4 2018
... has led to difficulties doingbusiness, including high operational costs for foreign companies. While Ghana is positioned as one of the more attractivepharmaceutical markets for multinational firms on a regional basis, generic products will maintain a ... Read More
-
Hong Kong Pharmaceuticals & Healthcare Q4 2018
... cope with a rapidly ageing population. On the private side too, the government has beenpromoting the development of private hospitals as part of its reform initiatives to improve the long-term sustainability of thecountry’s healthcare system. Read More
-
Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2018
... gene. In the presence of Wnt ligand, CTNNB1 acts as a coactivator for transcription factors of the TCF/LEF family, leading to activate Wnt responsive genes. It is involved in the regulation of cell adhesion, CDK2/PTPN6/CTNNB1/CEACAM1 ... Read More
-
Cancer Pain - Pipeline Review, H2 2018
... System) pipeline landscape. Cancer pain can be defined as a complex sensation that reflects both damage to the body and the body's response to the damage. Pain may arise due to tumor compressing or infiltrating ... Read More
-
Hairy Cell Leukemia - Pipeline Review, H2 2018
... Leukemia (Oncology) pipeline landscape. Hairy cell leukemia is a rare, slow-growing cancer of the blood in which bone marrow makes too many B cells (lymphocytes), a type of white blood cell that fights infection. Symptoms ... Read More
-
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Pipeline Review, H2 2018
... molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report Heparanase - Pipeline Review, H2 2018, outlays comprehensive information on the Heparanase (Endo Glucoronidase or Heparanase ... Read More
-
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Pipeline Review, H2 2018
... to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The latest report Type 2 Angiotensin II Receptor - Pipeline Review, H2 2018, outlays comprehensive information on ... Read More
-
Glycoprotein 41 (gp41) - Pipeline Review, H2 2018
... of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. Glycoprotein 41 (gp41) - Gp41 or glycoprotein 41 is a transmembrane protein that contains several sites within its ectodomain that are ... Read More
-
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Pipeline Review, H2 2018
... Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) pipeline Target constitutes close to 7 molecules. Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Protein kinase C ... Read More
-
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2018
... or C5) pipeline Target constitutes close to 33 molecules. Out of which approximately 29 molecules are developed by companies and remaining by the universities/institutes. The latest report Complement C5 - Pipeline Review, H2 2018, outlays ... Read More
-
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Pipeline Review, H2 2018
... Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - 11beta-hydroxysteroid dehydrogenase type 1 is an NADPH-dependent enzyme highly expressed in key metabolic tissues ... Read More
-
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Pipeline Review, H2 2018
... Review, H2 2018'; Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) pipeline Target constitutes close to 16 molecules. Out of which approximately 12 molecules are developed ... Read More
-
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Pipeline Review, H2 2018
... Growth Factor B (VEGF Related Factor or VEGFB) pipeline Target constitutes close to 7 molecules. Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Vascular endothelial growth factor B also known as VEGF-B ... Read More
-
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3
... EC 2.7.11.1 or EC 2.7.1.153) - Pipeline Review, H2 2018 Summary According to the recently published report 'Phosphatidylinositol 4,5 Bisphosphate 3 Kinase - Pipeline Review, H2 2018'; Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha ... Read More
-
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Pipeline Review, H2 2018
... or EC 2.7.11.26 or EC 2.7.11.1) pipeline Target constitutes close to 17 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Glycogen Synthase Kinase 3 ... Read More
-
Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H2 2018
... companies and remaining by the universities/institutes. The latest report Transforming Growth Factor Beta 1- Pipeline Review, H2 2018, outlays comprehensive information on the Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics, complete with analysis by ... Read More
-
Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Pipeline Review, H2 2018
... Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Transforming growth factor beta 2 (TGF-β2) is a polypeptide member of the transforming growth factor beta superfamily of ... Read More
-
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) - Pipeline Review, H2 2018
... Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) pipeline Target constitutes close to 15 molecules. Out of which approximately 14 molecules are developed ... Read More
-
Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Pipeline Review, H2 2018
... 2018 Summary Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Aurora Kinase ... Read More
-
India Pharmaceuticals & Healthcare Q1 2019
... the major emergingmarket for multinational pharmaceutical firms. Moreover, healthcare reforms bode well for pharmaceutical market development.Despite this, a tough pricing environment and low levels of intellectual property protection will remain ongoing concerns formultinational pharmaceutical firms. Read More
